{"disease":{"id":"high-risk-patient","name":"high risk patient"},"drugs":{"marketed":[{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"no-oac","indication_name":"Atrial Fibrillation or Flutter with a High Risk of Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF and at Least One Risk Factor for Stroke in Patients with a History of Stroke, TIA, or Non-Valvular AF","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"No OAC","generic_name":"no-oac","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Factor Xa","drug_class":"Direct Oral Anticoagulant","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":15,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06821711","title":"Optimal LDL-C Target in High-risk Patients After PCI","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05198960","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1308,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT05410171","title":"Machine Learning-based Early Clinical Warning of High-risk Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Southeast University, China","has_results":false},{"nct_id":"NCT04861337","title":"Remimazolam and Postoperative Nausea and Vomiting in High-risk Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":552,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06603272","title":"Comparison of Short- and Long-term Efficacy of Robotic Versus Laparoscopic Gastrectomy in High-risk Patients With Gastric Cancer: a Nationwide, Multicentre Cohort Study","phase":"","overall_status":"COMPLETED","enrollment_count":534,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03933306","title":"Intraoperative Goal-directed Blood Pressure and Dexmedetomidine on Outcomes","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":496,"lead_sponsor_name":"Peking University First Hospital","has_results":false},{"nct_id":"NCT06279663","title":"Management Tactics for Patients High Risk With Acute Coronary Syndrome Without ST Segment Elevation and Multivessel Coronary Artery Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Federal State Budgetary Institution National Medical Research Center named after academician E.N. Me","has_results":false},{"nct_id":"NCT06862765","title":"Characterization and Outcomes of Patients Screened for Transcatheter Tricuspid Valve Replacement","phase":"","overall_status":"COMPLETED","enrollment_count":340,"lead_sponsor_name":"Xijing Hospital","has_results":false},{"nct_id":"NCT05305053","title":"Practice Variation in Preoperative Multidisciplinary Team Discussions","phase":"","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"Rijnstate Hospital","has_results":false},{"nct_id":"NCT06713876","title":"Long-term Outcomes of Patients Undergoing ECMO-assisted PCI","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"Ling Tao, MD, PhD","has_results":false},{"nct_id":"NCT02155998","title":"Non-Interventional Study PREVENT","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03551717","title":"Retinal Microvascularization and Cardiovascular Disease","phase":"","overall_status":"TERMINATED","enrollment_count":155,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false},{"nct_id":"NCT03908658","title":"Inspiratory Muscle Training and Nasal High Flow in Difficult Weaning","phase":"NA","overall_status":"UNKNOWN","enrollment_count":146,"lead_sponsor_name":"Evangelismos Hospital","has_results":false},{"nct_id":"NCT03169569","title":"Efficacy of Hemostatic Powder in Preventing Bleeding After Gastric Endoscopic Submucosal Dissection in High-risk Patients: A Prospective Randomized Control Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":143,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT03356002","title":"Evaluation of C-Scan System in Providing Structural Information and Detection of Polypoid Lesions in High Risk Subjects","phase":"NA","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Check-Cap Ltd.","has_results":false},{"nct_id":"NCT02024776","title":"Effectiveness of Prehabilitation Program for High-risk Patients Underwent Abdominal Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Hospital Clinic of Barcelona","has_results":false},{"nct_id":"NCT04276870","title":"Orphan Indications for CD19 Redirected Autologous T Cells","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":133,"lead_sponsor_name":"Stephan Grupp MD PhD","has_results":false},{"nct_id":"NCT06284980","title":"Gestional Trophoblastic Neoplasia Ultrasound Assessment: Titanium Study","phase":"","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT01539746","title":"Transcatheter Aortic Valve Implantation Without Predilation","phase":"NA","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"University Hospital, Bonn","has_results":false},{"nct_id":"NCT05643430","title":"ULTRA LONG: BioFreedom Ultra","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":86,"lead_sponsor_name":"Biosensors Europe SA","has_results":false},{"nct_id":"NCT05482880","title":"Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region","phase":"","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT03684993","title":"Caries Prevention and Side Effects of Gum Arabic and Licorice Extracts Versus Chlorhexidine in High Caries Risk Patients","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06423833","title":"Trendelenburg Maneuver Versus Passive Leg Raising Test for Fluid Responsiveness in High-Risk Surgical Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Tanta University","has_results":false},{"nct_id":"NCT06822439","title":"Remote Fetal Monitoring in High Risk Pregnancies","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT07238764","title":"OCT-based DAPT Cessation in HBR Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","has_results":false},{"nct_id":"NCT04566120","title":"Streptococcus Mutans Cariogenicity by Real-time PCR in High Caries Risk Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT04254835","title":"Assessment of Inhibition of Biofilm Formation and Plaque Bacterial Count of Fluoride Varnish Containing Chlorhexidine and Cetylpyridinium Chloride Versus Conventional Fluoride Varnish","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":34,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06909136","title":"A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Suzhou Junjing BioSciences Co., Ltd.","has_results":false},{"nct_id":"NCT06736964","title":"Clinical Evaluation of Different Bioactive Restorative Materials for Cervical Carious in High Caries Risk Patients","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT03410069","title":"Monitoring Tissue Perfusion in Critically Ill or High-risk Surgical Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Advanced Perfusion Diagnostics","has_results":false},{"nct_id":"NCT05744622","title":"Clinical Evaluation of Chemically Cured Conventional Glass Ionomer After Light Emitting Diode Radiant Heat Enhancement","phase":"NA","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Suez Canal University","has_results":false},{"nct_id":"NCT07071961","title":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":16,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06046625","title":"Needs and Preferences of Patients With Head-neck Cutaneous SCC","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false}],"total":33},"guidelines":[],"source":"Drug Landscape verified database"}